ArticleJournal of cellular and molecular medicine2026
Valsartan Reduces Myocardial Ischemia-Reperfusion Injury by Inhibiting Ferritinophagy-Mediated Ferroptosis.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Revascularisation is the key therapeutic strategy for acute myocardial infarction (AMI). However, the opening of the 'culprit artery' is accompanied by myocardial ischemia-reperfusion injury (IRI), partially offsetting the benefits of revascularisation. At present, effective methods to alleviate myocardial IRI are lacking. Cardiomyocyte ferritinophagy induces myocardial ferroptosis and IRI. In the present study, the RT-PCR, western blotting, co-immunoprecipitation, and immunofluorescence co-localisation experiments revealed that hypoxia-reoxygenation (H/R) of cardiomyocytes induces the dephosphorylation of Mst1 at Thr183, a crucial autophagy inhibitory site. Its dephosphorylation impairs the phosphorylation of Beclin1 at Ser295, thereby potentiating ferritinophagy, triggering ferroptosis and exacerbating H/R-induced cardiomyocyte injury. In addition, valsartan restored the phosphorylation of Mst1 at Thr183 and Beclin1 at Ser295, thereby inhibiting myocardial ferritinophagy and ferroptosis. Valsartan also inhibits cardiomyocyte ferritinophagy by blocking the angiotensin II type 1 receptor. In vivo, valsartan ameliorated myocardial ferritinophagy, ferroptosis and IRI. However, following treatment with a ferroptosis inhibitor, valsartan failed to further alleviate myocardial IRI. In cardiomyocyte-specific Mst1 knockout mice, valsartan failed to suppress myocardial ferritinophagy and ferroptosis, and consequently showed no therapeutic efficacy against IRI. Pre-revascularisation administration of valsartan attenuated revascularisation-induced myocardial injury and improved cardiac function in patients with AMI. These findings suggest that valsartan may mitigate myocardial IRI and improve clinical outcomes in patients with AMI by regulating the AT
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.